If one person is scanned with one tau PET tracer and a second person, somewhere else, with another, can the results be compared? Can studies using different PET tracers be pooled for joint analysis?

In amyloid PET, visual and quantitative reads are at odds 6 percent of the time. In some instances, regional accumulation might be to blame. People with discordant scans accumulated amyloid faster ...

Professional Information ProfessorCentre de Neurologie Cognitive - CMRR Paris Nord Comments Without ApoE3 or ApoE4, Alzheimer’s Would be a Rare Disease 23 Jan 2026 ...

This approach uses mesenchymal stem cells isolated from a patient’s own fat tissue to treat neurodegenerative diseases. The stem cells are supposed to assist in repair of damaged tissue and ...

The A673T (“Icelandic”) mutation in APP is associated with protection against Alzheimer's disease and age-related cognitive decline. This knock-in rat model carries the Icelandic mutation and a ...

If a person with no cognitive complaints tests positive for brain amyloid based on plasma p-tau217, what should their doctor tell them about their likelihood of getting Alzheimer’s disease? That’s the ...

Contact Information Tugce Munise Satir, Master's, Ph.D. student Gothenburg, Sweden Education ...

Summary Two lines of transgenic mice that overexpress PSEN1 with the M146V mutation were developed simulataneously (line 8.2 and line 8.9) (Duff et al., 1996). Both lines have been crossed to Tg2576 ...

TASTPM is a double transgenic mouse model of Alzheimer’s disease carrying two mutations associated with early onset disease: the Swedish mutation in APP and the M146V mutation in PSEN1. The double ...

These parkin knockout (KO) mice were generated by creating a germline disruption in the parkin gene within exon 3 leading to a truncated transcript coding for the first 95 amino acids of mouse parkin ...

This mouse model was developed to investigate the effects of PINK1 deficiency (Kitada et al., 2007). The model involves a germline deletion of exons 4-7 of the endogenous Pink1 gene, creating ...

Masitinib maintained cognition and function in people with mild to moderate AD. The drug is believed to dampen inflammation via microglia and mast cells. An upcoming Phase 3 trial will include ...